Communications Biology (Apr 2021)
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
- Giorgia Maroni,
- Mahmoud A. Bassal,
- Indira Krishnan,
- Chee Wai Fhu,
- Virginia Savova,
- Rapolas Zilionis,
- Valerie A. Maymi,
- Nicole Pandell,
- Eva Csizmadia,
- Junyan Zhang,
- Barbara Storti,
- Julio Castaño,
- Riccardo Panella,
- Jia Li,
- Corinne E. Gustafson,
- Sam Fox,
- Rachel D. Levy,
- Claire V. Meyerovitz,
- Peter J. Tramontozzi,
- Kimberly Vermilya,
- Assunta De Rienzo,
- Stefania Crucitta,
- Daniela S. Bassères,
- Marla Weetall,
- Art Branstrom,
- Alessandra Giorgetti,
- Raffaele Ciampi,
- Marzia Del Re,
- Romano Danesi,
- Ranieri Bizzarri,
- Henry Yang,
- Olivier Kocher,
- Allon M. Klein,
- Robert S. Welner,
- Raphael Bueno,
- Maria Cristina Magli,
- John G. Clohessy,
- Azhar Ali,
- Daniel G. Tenen,
- Elena Levantini
Affiliations
- Giorgia Maroni
- Cancer Science Institute of Singapore, National University of Singapore
- Mahmoud A. Bassal
- Cancer Science Institute of Singapore, National University of Singapore
- Indira Krishnan
- Harvard Medical School
- Chee Wai Fhu
- Cancer Science Institute of Singapore, National University of Singapore
- Virginia Savova
- Department of Systems Biology, Harvard Medical School
- Rapolas Zilionis
- Department of Systems Biology, Harvard Medical School
- Valerie A. Maymi
- Beth Israel Deaconess Medical Center
- Nicole Pandell
- Beth Israel Deaconess Medical Center
- Eva Csizmadia
- Beth Israel Deaconess Medical Center
- Junyan Zhang
- Harvard Medical School
- Barbara Storti
- NEST, Scuola Normale Superiore and Istituto Nanoscienze-CNR
- Julio Castaño
- Platform for Immunotherapy BST-Hospital Clinic, Banc de Sang i Teixits (BST)
- Riccardo Panella
- Harvard Medical School
- Jia Li
- Cancer Science Institute of Singapore, National University of Singapore
- Corinne E. Gustafson
- Division of Thoracic Surgery, The Lung Center and the International Mesothelioma Program, Brigham and Women’s Hospital
- Sam Fox
- Division of Thoracic Surgery, The Lung Center and the International Mesothelioma Program, Brigham and Women’s Hospital
- Rachel D. Levy
- Division of Thoracic Surgery, The Lung Center and the International Mesothelioma Program, Brigham and Women’s Hospital
- Claire V. Meyerovitz
- Division of Thoracic Surgery, The Lung Center and the International Mesothelioma Program, Brigham and Women’s Hospital
- Peter J. Tramontozzi
- Division of Thoracic Surgery, The Lung Center and the International Mesothelioma Program, Brigham and Women’s Hospital
- Kimberly Vermilya
- Division of Thoracic Surgery, The Lung Center and the International Mesothelioma Program, Brigham and Women’s Hospital
- Assunta De Rienzo
- Harvard Medical School
- Stefania Crucitta
- Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa
- Daniela S. Bassères
- Biochemistry Department, Chemistry Institute, University of Sao Paulo
- Marla Weetall
- PTC Therapeutics, 100 Corporate Court
- Art Branstrom
- PTC Therapeutics, 100 Corporate Court
- Alessandra Giorgetti
- Cell Biology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, University of Barcelona
- Raffaele Ciampi
- Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa
- Marzia Del Re
- Unit of Clinical Pharmacology and Pharmacogenetics, Department of Laboratory Medicine, University Hospital of Pisa
- Romano Danesi
- Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa
- Ranieri Bizzarri
- NEST, Scuola Normale Superiore and Istituto Nanoscienze-CNR
- Henry Yang
- Cancer Science Institute of Singapore, National University of Singapore
- Olivier Kocher
- Harvard Medical School
- Allon M. Klein
- Department of Systems Biology, Harvard Medical School
- Robert S. Welner
- University of Alabama at Birmingham, Department of Medicine, Hemathology/Oncology
- Raphael Bueno
- Harvard Medical School
- Maria Cristina Magli
- Institute of Biomedical Technologies, National Research Council (CNR), Area della Ricerca di Pisa
- John G. Clohessy
- Harvard Medical School
- Azhar Ali
- Cancer Science Institute of Singapore, National University of Singapore
- Daniel G. Tenen
- Cancer Science Institute of Singapore, National University of Singapore
- Elena Levantini
- Harvard Medical School
- DOI
- https://doi.org/10.1038/s42003-021-01897-6
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 15
Abstract
Maroni, Bassal, Krishnan et al. characterise human non-small cell lung cancer (NSCLC) carrying Kras-mutations by single-cell RNA sequencing. They identify a tumour-specific population that is conserved in mice and responds to the drug, PTC596, which is currently in clinical trials and may offer a potential avenue for treating aggressive NSCLC expressing mutated Kras.
